Search

Your search keyword '"Karapanagiotou, Eleni"' showing total 191 results
Start Over Author "Karapanagiotou, Eleni"
191 results on '"Karapanagiotou, Eleni"'

1. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer

Author

Hughes, Daniel Johnathan, Josephides, Eleni, O’Shea, Robert, Manickavasagar, Thubeena, Horst, Carolyn, Hunter, Sarah, Tanière, Philippe, Nonaka, Daisuke, Van Hemelrijck, Mieke, Spicer, James, Goh, Vicky, Bille, Andrea, Karapanagiotou, Eleni, and Cook, Gary J. R.

Published
2024
Full Text
View/download PDF

2. 126 Exploring Real-World Treatment Patterns and Outcomes in Stage IIIA N2 Non-Small Cell Lung Cancer (NSCLC)

Author

Josephides, Eleni, primary, Dunn, Roberta, additional, Faranghi, Mona, additional, Henry, Annie-Rose, additional, Pilling, John, additional, Harrison-Phipps, Karen, additional, Ahmad, Shahreen, additional, Skwarski, Michael, additional, Taylor, Benjamin, additional, Spicer, James, additional, Georgiou, Alexandros, additional, Ghosh, Sharmistha, additional, Santis, George, additional, Breen, Ronan, additional, Van Hemelrijck, Mieke, additional, Karapanagiotou, Eleni, additional, Smith, Daniel, additional, and Bille, Andrea, additional

Published
2024
Full Text
View/download PDF

3. 35 Validation of published radiomics model to determine if CT parameters predict Programmed Death Ligand 1 expression in Non-Small Cell Lung Cancer

Author

Manickavasagar, Thubeena, primary, Manickavasagar, Thubeena, additional, Horst, Caroyln, additional, O'Shea, Robert, additional, Hughes, Daniel, additional, Josephides, Eleni, additional, Nonaka, Daisuke, additional, Bille, Andre, additional, Karapanagiotou, Eleni, additional, Cook, Gary, additional, and Goh, Vicky, additional

Published
2024
Full Text
View/download PDF

6. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer.

Author

Hughes, Daniel Johnathan, Josephides, Eleni, O'Shea, Robert, Manickavasagar, Thubeena, Horst, Carolyn, Hunter, Sarah, Tanière, Philippe, Nonaka, Daisuke, Van Hemelrijck, Mieke, Spicer, James, Goh, Vicky, Bille, Andrea, Karapanagiotou, Eleni, and Cook, Gary J. R.

Subjects
PROGRAMMED death-ligand 1, POSITRON emission tomography, NON-small-cell lung carcinoma, LEAN body mass, COMPUTED tomography
Abstract

Background: Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 expression are closely associated, and studies demonstrate correlation of PD-L1 with glucose metabolism. Aim: The aim of this study was to investigate the association of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) metabolic parameters with PD-L1 expression in primary lung tumour and lymph node metastases in resected NSCLC. Methods: We conducted a retrospective analysis of 210 patients with node-positive resectable stage IIB–IIIB NSCLC. PD-L1 tumour proportion score (TPS) was determined using the DAKO 22C3 immunohistochemical assay. Semi-automated techniques were used to analyse pre-operative [18F]FDG-PET/CT images to determine primary and nodal metabolic parameter scores (including max, mean, peak and peak adjusted for lean body mass standardised uptake values (SUV), metabolic tumour volume (MTV), total lesional glycolysis (TLG) and SUV heterogeneity index (HISUV)). Results: Patients were predominantly male (57%), median age 70 years with non-squamous NSCLC (68%). A majority had negative primary tumour PD-L1 (TPS < 1%; 53%). Mean SUVmax, SUVmean, SUVpeak and SULpeak values were significantly higher (p < 0.05) in those with TPS ≥ 1% in primary tumour (n = 210) or lymph nodes (n = 91). However, ROC analysis demonstrated only moderate separability at the 1% PD-L1 TPS threshold (AUCs 0.58–0.73). There was no association of MTV, TLG and HISUV with PD-L1 TPS. Conclusion: This study demonstrated the association of SUV-based [18F]FDG-PET/CT metabolic parameters with PD-L1 expression in primary tumour or lymph node metastasis in resectable NSCLC, but with poor sensitivity and specificity for predicting PD-L1 positivity ≥ 1%. Clinical relevance statement: Whilst SUV-based fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters may not predict programmed death-ligand 1 positivity ≥ 1% in the primary tumour and lymph nodes of resectable non-small cell lung cancer independently, there is a clear association which warrants further investigation in prospective studies. Trial registration: Non-applicable Key Points: • Programmed death-ligand 1 immunohistochemistry has a predictive role in non-small cell lung cancer immunotherapy; however, it is both heterogenous and dynamic. • SUV-based fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) metabolic parameters were significantly higher in primary tumour or lymph node metastases with positive programmed death-ligand 1 expression. • These SUV-based parameters could potentially play an additive role along with other multi-modal biomarkers in selecting patients within a predictive nomogram. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Problem Solving in Cancer and Fertility

Author

Karapanagiotou, Eleni M, Kopeika, Julia, Board, Ruth E, Archer, Caroline, Karapanagiotou, Eleni M, Kopeika, Julia, Board, Ruth E, Archer, Caroline and Karapanagiotou, Eleni M, Kopeika, Julia, Board, Ruth E, Archer, Caroline, Karapanagiotou, Eleni M, Kopeika, Julia, Board, Ruth E, Archer, Caroline

Published
2020

8. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial

Author

Evans, Ruth, Ball, Simon, Jannapureddy, Revanth, Mills-Baldock, Tina, Barhate, Kishor, Nagy, Zoltan, Raouf, Sherif, Aboagye, Akosa, Anand, Girija, Butawan, Rommel, Hadley, Elizabeth, Onajobi, Adesewa, Tarver, Kathryn, Nawaz, Tanjil, Norman, Catherine, Rich, Nathalie, Tulmuntaha, Sidra, Ahmed, Shafi, Lim, Louise, McKirdy, Fiona, Couture, Jenna, Ferdous, Shahanara, Julka, Payal, Mohammed, Ali, O'Shaughnessy, Terry, Ricketts, William, Jackson, Marie, Kay, Clive, Lowe, Andy, McGowan, Janet, Mohammed, Amjad, Robinson, Jon, Curry, Lara, Maheswaran, Sasithar, Ramesh, Subramanian, Riddle, Pippa, Balogun, Shaki, Campbell, Yvonne, Jeyadevan, Nelesh, Kavidasan, Aji, Locke, Imogen, Loke, Tuck-Kay, Olaleye, Ibiyemi, Collins, Clare, Green, Elizabeth, Prendergast, Colm, Win, Thida, Davis, Amy, Blakeway, Lyn, Gourtsoyianni, Sofia, Green, Adrian, Kelly-Morland, Christian, Naaseri, Sahar, Prezzi, Davide, Snell, David, Boisfer, Dorothee, Desai, Keyury, Hans, Balinder, Hans, Sophia, Ntala, Eleni, Alam, Adnam, Burke, Stephen, Bhowmik, Angshu, Bharwani, Nishat, Hanid, Gule, Honeyfield, Lesley, Stoycheva, Tina, Strickland, Nicola, Bazari, Farid, Beedham, Helen, De Los, Jane, Lauigan, Reyes, Limbu, Priya, Lucas, Nicola, O'Connor, Sally, Rhodes, Anita, Agoramoorthy, Laletha, Handousa, Martha, Jalloh, Abel, Stegner, Stefania, Wilson, Shanna, Birch, David, Chukundah, Suzanne, Phiri, Priscilla, Srirajaskanthan, Raj, Karapanagiotou, Eleni, Smith, Daniel, Syeed, Ferrial, van Someren, Chloe, Borgstein, Rudi, Roehrig, Jamila, Chao, David, Hurl, Lorraine, Gogbashian, Andrew, Nunes, Andre, Simcock, Ian, Stirling, James, Beable, Richard, Furneaux, Maureen, Gibbons, Nicola, Higginson, Antony, Curtis, Howard, Perry, Kitrick, Amadi, Anita, Hughes, Heather, Patel, Prital, Atkin, Gary, Elton, Colin, Karp, Stephen, Woodrow, Lisa, Yu, Dominic, Khan, Sajid, Rienhardt, Alistair, Datt, Pooja, Ilangovan, Rajapandian, Jenkins, Ian, Mahmud, Saba, Light, Teresa, Kellaway, Joanne, O'Callaghan, Ann, Partridge, William, Daniel, Amelia, Ekeowa, Ugo, Long, Michael, Russell, Peter, Scurr, Erica, Morgan, Veronica, Tunariu, Nina, Chang, Elizabeth, Hughes, Laura, Marwood, Ellice, Prior, Katie, Reddi, Meena, Sargus, Kara, Sharp, Abby, Beeston, Teresita, Isaac, Elizabeth, Jayme, Adoracion, Kalasthry, Jagadish, Piga, Wivijin, Rahman, Farzana, Weir, Shraddha, Austria, Aileen, Crosbie, James, Engledow, Alec, McCullogh, Jonathan, Obichere, Austen, Shiu, Kai-Keen, Wanstall, Christopher, Simeon, Celia, Smith, Amy, Bateman, Andrew, Breen, David, Davis, Liane, Everitt, Chris, Johnson, Alice, Nichols, Paul, Shepherd, Beth, Gilbert, Kayleigh, Verjee, Azmina, Saull, Michelle, Wilson, Jonathan, Adeniba, Rashidat, Conteh, Veronica, Howling, Sarah, Lock, Sara, Taylor, Stuart A, Mallett, Sue, Beare, Sandy, Bhatnagar, Gauraang, Blunt, Dominic, Boavida, Peter, Bridgewater, John, Clarke, Caroline S, Duggan, Marian, Ellis, Steve, Glynne-Jones, Robert, Goh, Vicky, Groves, Ashley M, Hameeduddin, Ayshea, Janes, Sam M, Johnston, Edward W, Koh, Dow-Mu, Miles, Anne, Morris, Stephen, Morton, Alison, Navani, Neal, O'Donohue, John, Oliver, Alfred, Padhani, Anwar R, Pardoe, Helen, Patel, Uday, Punwani, Shonit, Quinn, Laura, Rafiee, Hameed, Reczko, Krystyna, Rockall, Andrea G, Shahabuddin, Khawaja, Sidhu, Harbir S, Teague, Jonathan, Thaha, Mohamed A, Train, Matthew, van Ree, Katherine, Wijeyekoon, Sanjaya, and Halligan, Steve

Published
2019
Full Text
View/download PDF

9. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial

Author

Evans, Ruth, Shahabuddin, Khawaja, Jannapureddy, Revanth, Mills-Baldock, Tina, Barhate, Kishor, Nagy, Zoltan, Raouf, Sherif, Aboagye, Akosa, Anand, Girija, Butawan, Rommel, Hadley, Elizabeth, Onajobi, Adesewa, Thaha, Mohamed A, Nawaz, Tanjil, Norman, Catherine, Rich, Nathalie, Tulmuntaha, Sidra, Ahmed, Shafi, Lim, Louise, McKirdy, Fiona, Couture, Jenna, Ferdous, Shahanara, Julka, Payal, Mohammed, Ali, Pardoe, Helen, Wijeyekoon, Sanjaya, Van Ree, Katherine, Blunt, Dominic, Ricketts, William, Jackson, Marie, Kay, Clive, Lowe, Andy, McGowan, Janet, Mohammed, Amjad, Robinson, Jon, Curry, Lara, Maheswaran, Sasithar, Ramesh, Subramanian, Riddle, Pippa, Balogun, Shaki, Campbell, Yvonne, Jeyadevan, Nelesh, Kavidasan, Aji, Locke, Imogen, Loke, Tuck-Kay, Olaleye, Ibiyemi, Collins, Clare, Green, Elizabeth, Prendergast, Colm, Win, Thida, Davis, Amy, Blakeway, Lyn, Gourtsoyianni, Sofia, Green, Adrian, Kelly-Morland, Christian, Naaseri, Sahar, O'Donohue, John, Snell, David, Boisfer, Dorothee, Desai, Keyury, Hans, Balinder, Hans, Sophia, Ntala, Eleni, Alam, Adnam, Burke, Stephen, Train, Matthew, Bharwani, Nishat, Hanid, Gule, Honeyfield, Lesley, Stoycheva, Tina, Patel, Uday, Bazari, Farid, Beedham, Helen, De Los, Jane, Lauigan, Reyes, Limbu, Priya, Lucas, Nicola, O'Connor, Sally, Rhodes, Anita, Agoramoorthy, Laletha, Handousa, Martha, Jalloh, Abel, Stegner, Stefania, Wilson, Shanna, Birch, David, Chukundah, Suzanne, Phiri, Priscilla, Srirajaskanthan, Raj, Karapanagiotou, Eleni, Smith, Daniel, Syeed, Ferrial, van Someren, Chloe, Borgstein, Rudi, Roehrig, Jamila, Chao, David, Hurl, Lorraine, Gogbashian, Andrew, Nunes, Andre, Simcock, Ian, Stirling, James, Beable, Richard, Furneaux, Maureen, Gibbons, Nicola, Higginson, Antony, Curtis, Howard, Perry, Kitrick, Amadi, Anita, Hughes, Heather, Patel, Prital, Atkin, Gary, Elton, Colin, Karp, Stephen, Woodrow, Lisa, Yu, Dominic, Khan, Sajid, Rienhardt, Alistair, Datt, Pooja, Ilangovan, Rajapandian, Jenkins, Ian, Mahmud, Saba, Light, Teresa, Kellaway, Joanne, O'Callaghan, Ann, Partridge, William, Daniel, Amelia, Ekeowa, Ugo, Long, Michael, Scurr, Erica, Morgan, Veronica, Tunariu, Nina, Chang, Elizabeth, Hughes, Laura, Marwood, Ellice, Prior, Katie, Reddi, Meena, Sargus, Kara, Sharp, Abby, Beeston, Teresita, Isaac, Elizabeth, Jayme, Adoracion, Kalasthry, Jagadish, Piga, Wivijin, Rahman, Farzana, Weir, Shraddha, Austria, Aileen, Crosbie, James, Engledow, Alec, McCullogh, Jonathan, Obichere, Austen, Shiu, Kai-Keen, Wanstall, Christopher, Simeon, Celia, Smith, Amy, Bateman, Andrew, Breen, David, Davis, Liane, Everitt, Chris, Johnson, Alice, Nichols, Paul, Shepherd, Beth, Gilbert, Kayleigh, Verjee, Azmina, Saull, Michelle, Wilson, Jonathan, Adeniba, Rashidat, Conteh, Veronica, Howling, Sarah, Taylor, Stuart A, Mallett, Sue, Ball, Simon, Beare, Sandy, Bhatnagar, Gauraang, Bhowmik, Angshu, Boavida, Peter, Bridgewater, John, Clarke, Caroline S, Duggan, Marian, Ellis, Steve, Glynne-Jones, Robert, Goh, Vicky, Groves, Ashley M, Hameeduddin, Ayshea, Janes, Sam M, Johnston, Edward W, Koh, Dow-Mu, Lock, Sara, Miles, Anne, Morris, Stephen, Morton, Alison, Navani, Neal, Oliver, Alfred, O'Shaughnessy, Terry, Padhani, Anwar R, Prezzi, David, Punwani, Shonit, Quinn, Laura, Rafiee, Hameed, Reczko, Krystyna, Rockall, Andrea G, Russell, Peter, Sidhu, Harbir S, Strickland, Nicola, Tarver, Kathryn, Teague, Jonathan, and Halligan, Steve

Published
2019
Full Text
View/download PDF

15. Supplementary Data from Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

Author

Harrington, Kevin J., primary, Karapanagiotou, Eleni M., primary, Roulstone, Victoria, primary, Twigger, Katie R., primary, White, Christine L., primary, Vidal, Laura, primary, Beirne, Debbie, primary, Prestwich, Robin, primary, Newbold, Kate, primary, Ahmed, Merina, primary, Thway, Khin, primary, Nutting, Christopher M., primary, Coffey, Matt, primary, Harris, Dean, primary, Vile, Richard G., primary, Pandha, Hardev S., primary, DeBono, Johann S., primary, and Melcher, Alan A., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 2 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Author

Karapanagiotou, Eleni M., primary, Roulstone, Victoria, primary, Twigger, Katie, primary, Ball, Mercel, primary, Tanay, MaryAnne, primary, Nutting, Chris, primary, Newbold, Kate, primary, Gore, Martin E., primary, Larkin, James, primary, Syrigos, Konstantinos N., primary, Coffey, Matt, primary, Thompson, Brad, primary, Mettinger, Karl, primary, Vile, Richard G., primary, Pandha, Hardev S., primary, Hall, Geoff D., primary, Melcher, Alan A., primary, Chester, John, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 1 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Author

Karapanagiotou, Eleni M., primary, Roulstone, Victoria, primary, Twigger, Katie, primary, Ball, Mercel, primary, Tanay, MaryAnne, primary, Nutting, Chris, primary, Newbold, Kate, primary, Gore, Martin E., primary, Larkin, James, primary, Syrigos, Konstantinos N., primary, Coffey, Matt, primary, Thompson, Brad, primary, Mettinger, Karl, primary, Vile, Richard G., primary, Pandha, Hardev S., primary, Hall, Geoff D., primary, Melcher, Alan A., primary, Chester, John, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure Legends 1-3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Author

Karapanagiotou, Eleni M., primary, Roulstone, Victoria, primary, Twigger, Katie, primary, Ball, Mercel, primary, Tanay, MaryAnne, primary, Nutting, Chris, primary, Newbold, Kate, primary, Gore, Martin E., primary, Larkin, James, primary, Syrigos, Konstantinos N., primary, Coffey, Matt, primary, Thompson, Brad, primary, Mettinger, Karl, primary, Vile, Richard G., primary, Pandha, Hardev S., primary, Hall, Geoff D., primary, Melcher, Alan A., primary, Chester, John, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Author

Karapanagiotou, Eleni M., primary, Roulstone, Victoria, primary, Twigger, Katie, primary, Ball, Mercel, primary, Tanay, MaryAnne, primary, Nutting, Chris, primary, Newbold, Kate, primary, Gore, Martin E., primary, Larkin, James, primary, Syrigos, Konstantinos N., primary, Coffey, Matt, primary, Thompson, Brad, primary, Mettinger, Karl, primary, Vile, Richard G., primary, Pandha, Hardev S., primary, Hall, Geoff D., primary, Melcher, Alan A., primary, Chester, John, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

20. Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

Author

Hughes, Daniel Johnathan, primary, Kapiris, Matthaios, additional, Podvez Nevajda, Andreja, additional, McGrath, Harriet, additional, Stavraka, Chara, additional, Ahmad, Shahreen, additional, Taylor, Benjamin, additional, Cook, Gary J. R., additional, Ghosh, Sharmistha, additional, Josephs, Debra, additional, Pintus, Elias, additional, Gennatas, Spyridon, additional, Bille, Andrea, additional, Ryanna, Kimuli, additional, Santis, George, additional, Montes, Ana, additional, Van Hemelrijck, Mieke, additional, Karapanagiotou, Eleni, additional, Smith, Daniel, additional, Spicer, James, additional, and Georgiou, Alexandros, additional

Published
2022
Full Text
View/download PDF

21. [99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression.

Author

Nazir, Muhummad Sohaib, Hughes, Daniel Johnathan, Chand, Gitasha, Adamson, Kathryn, Johnson, Jessica, Bailey, Damion, Gibson, Victoria, Ting, Hong Hoi, Lyon, Alexander R., Cook, Gary J. R., PECan study group, Edmonds, Scott, Georgiou, Alexandros, Karapanagiotou, Eleni, Josephs, Debra, McLean, Emma, Spicer, James, and Goh, Vicky

Subjects
MYOCARDIAL perfusion imaging, IMMUNOGLOBULINS, MYOCARDIUM, COMPUTED tomography, PROGRAMMED death-ligand 1, MAJOR adverse cardiovascular events, SINGLE-photon emission computed tomography, BIOMARKERS
Abstract

Background: Myocardial programmed death-ligand 1 (PD-L1) expression is implicated in immune checkpoint inhibitor (ICI)-associated myocarditis. Measurement of myocardial PD-L1 expression may have potential use as a mechanistic and predictive biomarker. The aim of this study was to determine non-invasive assessment of myocardial PD-L1 expression using [99mTc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT. Methods: Thoracic [99mTc]NM-01 SPECT/CT was performed in lung cancer patients (n = 10) at baseline and 9-weeks following anti-programmed cell death protein 1 (PD-1) therapy. Baseline and 9-week left ventricular and right ventricular to blood pool ratios (LVmax:BP) and (RVmax:BP) were measured. LVmax was compared to background skeletal muscle (musclemax). Intra-rater reliability was determined by intraclass correlation coefficient (ICC) and Bland–Altman analysis. Results: Mean LVmax:BP values were 2.76 ± 0.67 at baseline vs 2.55 ± 0.77 at 9 weeks (p = 0.42). Mean RVmax:BP was 1.82 ± 0.32 at baseline vs 1.76 ± 0.45 at 9 weeks (p = 0.67). Myocardial PD-L1 expression was at least threefold greater than skeletal muscle at baseline for the LV (LVmax to musclemax 3.71 ± 0.77 vs 0.98 ± 0.20 (p < 0.001)) and at least twofold for the RV (LVmax to musclemax 2.49 ± 0.63 vs 0.98 ± 0.20 (p < 0.001)). There was excellent intra-rater reliability for LVmax:BP with ICC 0.99 (95% confidence interval 0.94–0.99, p < 0.001), mean bias -0.05 ± 0.14 (95% limits of agreement -0.32 to 0.21). There were no major adverse cardiovascular events or myocarditis during follow-up. Conclusion: This study is the first to report PD-L1 expression of the heart that can be quantified non-invasively without invasive myocardial biopsy, with high reliability and specificity. This technique can be applied to investigate myocardial PD-L1 expression in ICI-associated myocarditis and cardiomyopathies. Clinical trial registration PD-L1 Expression in Cancer (PECan) study (NCT04436406). https://clinicaltrials.gov/ct2/show/NCT04436406 June 18th, 2020. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data

Author

Younan, Helen-Cara, primary, Zhang, Shuai, additional, Monroy, Maria, additional, Almusarhed, Manar, additional, Julve, Max, additional, Roy, Debashree, additional, Toghey, Sopozme, additional, Ahmed, Zartaj, additional, Slater, Stephanie, additional, Altharwane, Shaymaa, additional, Giorgiou, Alex, additional, Ghosh, Sharmistha, additional, Gennatas, Spyridon, additional, Karapanagiotou, Eleni, additional, Montes, Ana, additional, Pintus, Elias, additional, Spicer, James, additional, Shah, Riyaz, additional, Ahmed, Samreen, additional, Newsom-Davis, Tom, additional, Mohammed, Waleed, additional, Power, Danielle, additional, Evans, Joanne, additional, Hatcher, Olivia, additional, Lakhani, Amish, additional, Samani, Amit, additional, and Josephs, Debra, additional

Published
2022
Full Text
View/download PDF

27. Abstract P1-17-08: Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience

Author

Battisti, Nicolò Matteo Luca, primary, Morrison, Laura, additional, Nash, Tamsin, additional, Senthivel, Nishanti, additional, Kestenbaum, Samantha, additional, Begum, Parvin, additional, Obeid, Mariam, additional, Hayhurst, William, additional, Yang, Dorothy, additional, Gafoor, Shafiah, additional, Brown, Caroline, additional, Rehman, Farah, additional, Kenny, Laura, additional, Hatcher, Olivia, additional, Susan, Susan, additional, Williams, Jennet, additional, Brown, Anna, additional, Rozati, Hamoun, additional, Alexandros, Alexandros, additional, Sawyer, Elinor, additional, Gousis, Charalampos, additional, Karapanagiotou, Eleni, additional, Rigg, Anna, additional, Rapti, Kleopatra, additional, Roylance, Rebecca, additional, Beresford, Mark, additional, Gee, Abigail L, additional, Konstantis, Apostolos, additional, King, Judy, additional, Nathan, Mark, additional, Spurrell, Emma, additional, Pearce, Mark, additional, Bradwell, Dane, additional, Denton, Arshi, additional, Swain, Kate, additional, McGrath, Sophie, additional, Allen, Mark, additional, Ring, Alistair, additional, Johnston, Stephen, additional, and Raja, Fharat, additional

Published
2022
Full Text
View/download PDF

28. Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFR mutation and small cell transformation

Author

Hughes, Daniel Johnathan, primary, Cook, Gary JR, additional, McLean, Emma, additional, Smith, Daniel, additional, King, Juliet, additional, Diamantopoulos, Athanasios, additional, Jones, Aled, additional, Neat, Michael, additional, Santis, George, additional, Spicer, James, additional, Karapanagiotou, Eleni, additional, and Georgiou, Alexandros, additional

Published
2021
Full Text
View/download PDF

44. A retrospective evaluation of PD-L1 expression on primary non-small cell lung cancer (NSCLC) samples and associated involved hilar or mediastinal lymph nodes (N1 or N2) (REPLICA).

Author

Karapanagiotou, Eleni, primary, Bille, Andrea, additional, Taniere, Philippe, additional, Flash, Clare, additional, Douiri, Abdel, additional, Willis, Elizabeth, additional, Kandasamy, Srivani, additional, Curinga, Domenico, additional, Velamuri, Shriram, additional, and Nonaka, Daisuke, additional

Published
2020
Full Text
View/download PDF

50. 66 - Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data

Author

Younan, Helen-Cara, Zhang, Shuai, Monroy, Maria, Almusarhed, Manar, Julve, Max, Roy, Debashree, Toghey, Sopozme, Ahmed, Zartaj, Slater, Stephanie, Altharwane, Shaymaa, Giorgiou, Alex, Ghosh, Sharmistha, Gennatas, Spyridon, Karapanagiotou, Eleni, Montes, Ana, Pintus, Elias, Spicer, James, Shah, Riyaz, Ahmed, Samreen, Newsom-Davis, Tom, Mohammed, Waleed, Power, Danielle, Evans, Joanne, Hatcher, Olivia, Lakhani, Amish, Samani, Amit, and Josephs, Debra

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results